Advertisement

Hormones

, Volume 17, Issue 2, pp 247–253 | Cite as

The low levels of bone morphogenic protein-4 and its antagonist noggin in type 2 diabetes

  • Banu Sarer Yurekli
  • Gokcen Unal Kocabas
  • Murat Aksit
  • Nilufer Ozdemir Kutbay
  • Aslı Suner
  • Ismail Yurekli
  • Habib Cakir
  • Giray Bozkaya
  • Sevki Cetinkalp
Original Article

Abstract

Objective

Bone morphogenic protein-4 (BMP-4) is a proinflammatory cytokine which is controlled by BMP-4 antagonists. Our aim was to investigate the levels of BMP-4 and its antagonists, noggin and matrix Gla protein (MGP), in prediabetes and diabetes.

Design

One hundred and forty-two type 2 diabetic, 32 prediabetic, and 58 control subjects participated in this cross-sectional study. BMP-4, noggin, and MGP were measured with the ELISA method.

Results

There was a significant difference between the three groups in relation to sex, hypertension, fasting plasma glucose, HbA1c, lipid profiles, and diastolic blood pressure (p < 0.05). BMP-4 levels were significantly lower in the diabetic group compared to the control group (108.5 and 127.5 ng/mL, respectively, p < 0.001 diabetes vs. control). Noggin levels were significantly lower in the diabetic group compared to the prediabetic and control groups (10.5, 11.5, and 12.0 ng/mL, as median, respectively, p < 0.001; diabetes vs. control, p = 0.002; diabetes vs. prediabetes). BMP-4 was associated significantly with noggin in the entire study population (ß coefficient = 0.796, p < 0.001). Receiver operating characteristic (ROC) curve analysis showed that the area under the ROC curve was 0.708 (95% CI 0.551–0.864, p = 0.011) for BMP-4 levels. The optimal cutoff value of BMP-4 for detecting albuminuria was 118.5 ng/mL for which sensitivity was 71.4% and specificity was 66.4%.

Conclusions

BMP-4 and noggin levels were lower in the diabetic group. High BMP-4 levels were significantly associated with albuminuria. Further studies are warranted to determine the role of BMP-4 in the pathogenic processes underlying albuminuria and hyperglycemia in patients with type 2 diabetes.

Keywords

BMP-4 Antagonists Urinary albumin excretion 

Notes

Funding information

This work was supported by the Ege University Scientific Research Project Committee, with project number 2015-TIP-034.

Compliance with ethical standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Bax JJ, Young LH, Frye RL, Bonow RO, Steinberg HO, Barrett EJ (2007) Screening for coronary artery disease in patients with diabetes. Diabetes Care 30:2729–2736CrossRefPubMedGoogle Scholar
  2. 2.
    Sorescu GP, Sykes M, Weiss D et al (2003) Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress stimulates an inflammatory response. J Biol Chem 278:31128–31135CrossRefPubMedGoogle Scholar
  3. 3.
    Cui Y, Jean F, Thomas G, Christian JL (1998) BMP-4 is proteolytically activated by furin and/or PC6 during vertebrate embryonic development. EMBO J 17:4735–4743CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Wong MC, Zhang Y, Huang Y (2014) Bone morphogenic protein-4-induced oxidant signaling via protein carbonylation for endothelial dysfunction. Free Radic Biol Med 75:178–190.  https://doi.org/10.1016/j.freeradbiomed.2014.07.035 CrossRefPubMedGoogle Scholar
  5. 5.
    Son JW, Jang EH, Kim MK et al (2011) Serum BMP-4 levels in relation to arterial stiffness and carotid atherosclerosis in patients with type 2 diabetes. Biomark Med 5:827–835.  https://doi.org/10.2217/bmm.11.81 CrossRefPubMedGoogle Scholar
  6. 6.
    Miriyala S, Gongora Nieto MC, Mingone C et al (2006) Bone morphogenic protein-4 induces hypertension in mice: role of noggin, vascular NADPH oxidases, and impaired vasorelaxation. Circulation 113:2818–2825CrossRefPubMedGoogle Scholar
  7. 7.
    Yao Y, Shahbazian A, Boström KI (2008) Proline and gamma-carboxylated glutamate residues in matrix Gla protein are critical for binding of bone morphogenetic protein-4. Circ Res 102:1065–1074.  https://doi.org/10.1161/CIRCRESAHA.107.166124 CrossRefPubMedGoogle Scholar
  8. 8.
    Chang K, Weiss D, Suo J et al (2007) Bone morphogenic protein antagonists are coexpressed with bone morphogenic protein 4 in endothelial cells exposed to unstable flow in vitro in mouse aortas and in human coronary arteries: role of bone morphogenic protein antagonists in inflammation and atherosclerosis. Circulation 116:1258–1266CrossRefPubMedGoogle Scholar
  9. 9.
    Balemans W, Van Hul W (2002) Extracellular regulation of BMP signaling in vertebrates: a cocktail of modulators. Dev Biol 250:231–250CrossRefPubMedGoogle Scholar
  10. 10.
    Tominaga T, Abe H, Ueda O (2011) Activation of bone morphogenetic protein 4 signaling leads to glomerulosclerosis that mimics diabetic nephropathy. J Biol Chem 286:20109–20116CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Agarwal A, Hegde A, Yadav C, Ahmad A, Manjrekar PA, Srikantiah RM (2016) Assessment of oxiative stress and inflammation in prediabetes—a hospital based cross-sectional study. Diabetes Metab Syndr 10(2 Suppl 1):S123–S126.  https://doi.org/10.1016/j.dsx.2016.03.009 CrossRefPubMedGoogle Scholar
  12. 12.
    American Diabetes Association (2015) Diagnosis and classification of diabetes mellitus. Diabetes Care 38:S8–S16CrossRefGoogle Scholar
  13. 13.
    Bendermacher BL, Teijink JA, Willigendael EM et al (2012) Applicability of the ankle-brachial-index measurement as screening device for high cardiovascular risk: an observational study. BMC Cardiovasc Disord 12:59.  https://doi.org/10.1186/1471-2261-12-59 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    McDermott MM, Greenland P, Liu K et al (2002) The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study. Ann Intern Med 136:873–883CrossRefPubMedGoogle Scholar
  15. 15.
    Makhdoomi K, Mohammadi A, Yekta Z, Aghasi MR, Zamani N, Vossughian S (2013) Correlation between ankle-brachial index and microalbuminuria in type 2 diabetes mellitus. Iranian J Kidney Dis 7:204–209Google Scholar
  16. 16.
    National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39:S1–S266Google Scholar
  17. 17.
    Boström KI, Jumabay M, Matveyenko A, Nicholas SB, Yao Y (2011) Activation of vascular bone morphogenetic protein signaling in diabetes mellitus. Circ Res 108:446–457CrossRefPubMedGoogle Scholar
  18. 18.
    Son JW, Kim MK, Park YM et al (2010) Association of serum bone morphogenetic protein 4 levels with obesity and metabolic syndrome in non-diabetic individuals. Endocr J 58:39–46 Epub 2010 Dec 21CrossRefPubMedGoogle Scholar
  19. 19.
    Kim MK, Jang EH, Hong OK et al (2013) Changes in serum levels of bone morphogenic protein 4 and inflammatory cytokines after bariatric surgery in severely obese korean patients with type 2 diabetes. Int J Endocrinol 681205.  https://doi.org/10.1155/2013/681205
  20. 20.
    Vogt RR, Unda R, Yeh LC, Vidro EK, Lee JC, Tsin AT (2006) Bone morphogenetic protein-4 enhances vascular endothelial growth factor secretion by human retinal pigment epithelial cells. J Cell Biochem 98:1196–1202CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    San Martin A, Du P, Dikalova A et al (2007) Reactive oxygen species-selective regulation of aortic inflammatory gene expression in type 2 diabetes. Am J Physiol Heart Circ Physiol 292:H2073–H2082CrossRefPubMedGoogle Scholar
  22. 22.
    Derwall M, Malhotra R, Lai CS et al (2012) Inhibition of bone morphogenetic protein signaling reduces vascular calcification and atherosclerosis. Arterioscler Thromb Vasc Biol 32:613–622CrossRefPubMedGoogle Scholar
  23. 23.
    Koga M, Engberding N, Dikalova AE et al (2013) The bone morphogenic protein inhibitor, noggin, reduces glycemia and vascular inflammation in db/db mice. Am J Physiol Heart Circ Physiol 305:H747–H755CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2018

Authors and Affiliations

  • Banu Sarer Yurekli
    • 1
  • Gokcen Unal Kocabas
    • 2
  • Murat Aksit
    • 3
  • Nilufer Ozdemir Kutbay
    • 1
  • Aslı Suner
    • 4
  • Ismail Yurekli
    • 5
  • Habib Cakir
    • 5
  • Giray Bozkaya
    • 3
  • Sevki Cetinkalp
    • 1
  1. 1.Department of EndocrinologyEge University Faculty of MedicineIzmirTurkey
  2. 2.Department of EndocrinologyBozyaka Education and Research HospitalIzmirTurkey
  3. 3.Department of BiochemistryBozyaka Education and Research HospitalIzmirTurkey
  4. 4.Department of Biostatistics and Medical InformaticsEge University Faculty of MedicineIzmirTurkey
  5. 5.Department of Cardiovascular SurgeryIzmir Ataturk Education and Research HospitalIzmirTurkey

Personalised recommendations